ALKBH5 promotes the progression of cisplatin-resistant oral squamous cell carcinoma by regulating FOXA1 expression via m6A RNA methylation
DARU Journal of Pharmaceutical Sciences · 06.06.2026 · 34 (2)
DOI: 10.1007/s40199-026-00614-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, online erschienen am 06.06.2026. Verfasst von Ying Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Outpatient Department, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University…. Hauptthemen laut MEDLINE: AlkB Homolog 5, RNA Demethylase, Carcinoma, Squamous Cell, Cisplatin, Drug Resistance, Neoplasm. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Oral squamous cell carcinoma (OSCC) accounts for the vast majority of oral cancer cases. Accumulating evidence has implicated both AlkB homolog 5 (ALKBH5) and forkhead box protein A1 (FOXA1) in the emergence of cisplatin resistance in OSCC. This study aimed to define their functional roles and elucidate the underlying molecular mechanisms. METHODS: The expression of ALKBH5, FOXA1, and YTHDF2 was assessed by qPCR and Western blot. Cisplatin-resistant cell lines (H357 CisR and SCC4 CisR) were established via stepwise dose escalation. To investigate key functional phenotypes, a series of assays were employed: CCK-8 for viability, colony formation for proliferation, and Transwell for migration and invasion. Bioinformatics (SRAMP, RM2Target) predicted m⁶A sites on FOXA1 and its binding with ALKBH5, which were validated by MeRIP-qPCR and RIP. FOXA1 mRNA stability was measured by actinomycin D assay. RESULTS: ALKBH5 and FOXA1 were upregulated in cisplatin-resistant OSCC, with FOXA1 essential for maintaining oncogenic phenotypes. Bioinformatic and biochemical analyses confirmed FOXA1 as a direct target of ALKBH5. ALKBH5 demethylates FOXA1 mRNA, stabilizing its transcript and enhancing its expression by inhibiting YTHDF2-mediated degradation. Functionally, ALKBH5 overexpression reversed the tumor-suppressive effects of FOXA1 knockdown. CONCLUSION: A-dependent demethylation of FOXA1 transcripts, highlighting the ALKBH5-FOXA1 axis as a promising therapeutic target for overcoming this resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fifth Outpatient Department, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China.
- The Fifth Outpatient Department, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, China. qifeng_Geng@163.com.
Zitieren
APA
Wang, Y., Yang, H. X., Gu, Y. J., Tian, M., & Geng, Q. F. (2026). ALKBH5 promotes the progression of cisplatin-resistant oral squamous cell carcinoma by regulating FOXA1 expression via m6A RNA methylation. DARU Journal of Pharmaceutical Sciences, 34(2). https://doi.org/10.1007/s40199-026-00614-0
Vancouver
Wang Y, Yang HX, Gu YJ, Tian M, Geng QF. ALKBH5 promotes the progression of cisplatin-resistant oral squamous cell carcinoma by regulating FOXA1 expression via m6A RNA methylation. DARU Journal of Pharmaceutical Sciences. 2026;34(2). doi:10.1007/s40199-026-00614-0
BibTeX
@article{Wang2026,
author = {Wang, Ying and Yang, Hui-Xin and Gu, Yu-Jia and Tian, Mei and Geng, Qi-Feng},
title = {ALKBH5 promotes the progression of cisplatin-resistant oral squamous cell carcinoma by regulating FOXA1 expression via m6A RNA methylation},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
volume = {34},
number = {2},
doi = {10.1007/s40199-026-00614-0}
}
EUVIMED